Novartis terminates collaboration and license pact with Sangamo

According to a regulatory filing, on March 13, 2023, Novartis Institutes for BioMedical Research, Inc. (NVS) notified Sangamo Therapeutics (SGMO) of its termination for convenience, effective June 11, 2023, of the Collaboration and License Agreement by and between Novartis and Sangamo dated July 27, 2020, pursuant to which Novartis and Sangamo were engaged in programs to research gene regulation therapies to treat three neurodevelopment disorders. Novartis has indicated to Sangamo that the termination relates to a recent strategic review. Sangamo will investigate alternative options to advance the neurodevelopmental disorder programs that were subject to the Novartis Agreement, including potential development internally or with a collaboration partner, dependent on the outcome of a broader strategic review of its pre-clinical pipeline of therapies to treat patients suffering from central nervous system disorders.